Direct answer:A suitable pharmaceutical manufacturing, repackaging, relabelling or recycling facility shall be registered with the FDA according to its actual activities. The offshore facility must be registered before the drug is intended to be imported into the United States; Renewed from 1 October to 31 December of each year. Registration, Labeler Code and Drug Listing are different records and the facility renewal cannot automatically replace the product listing maintenance.

The physical facilities and activities are checked before registration is arranged. Brand companies, trading companies and manufacturing sites cannot replace each other; Complete registration is not equal to obtaining FDA approval or cGMP inspection.

I. Which facilities and activities need to be reconciled?

The registration requirements for facilities such as manufacturing, repackaging, relabelling or recycling should be checked around the medicines and actual activities for distribution in the United States and the application of specific exceptions should be judged. Only facilities that are legally required to be registered should be registered, and registration should not be treated as a marketing qualification that any enterprise can apply for.

When the same group has multiple sites, the actual address and activity should be checked on a case-by-case basis; Companies that sell or hold brands alone cannot automatically register their brand office as a substitute for a plant because the product is produced by another plant.

II. What is the difference between facility registration and Labeler Code, listing?

  • Facilities register to identify actual pharmaceutical facilities, operations and information on related responsibilities.
  • The Labeler Code identifies pharmaceutical marketing-related companies, which are part of the NDC and are not a substitute for the registration of facilities.
  • Drug Listing submits and maintains information based on actual medicines, labels, packaging and production facilities.

First-time projects to refer toProcess of registration of medicines; For coding and product-specific data seeDrug Listing and NDC Guide。

III. What information is to be prepared for offshore facilities?

  • The name of the facility in English, the actual address, the DUNS of the corresponding location and the actual operation of the facility.
  • Contact person to receive communication related to the FDA facility.
  • U.S. agent, authorized and applicable DUNS information.
  • All applicable information, such as known importers, and relevant supply chain and communication arrangements.
  • Registered, recently accepted SPL, account permissions and historical change records are available.

The FDA requires that DUNS, the physical facility, be checked instead of applying the company headquarters number directly. Where names, addresses or subjects are inconsistent, the reasons should be verified to avoid filling with information on other sites that can be accessed in the system.

IV. How can first registration proceed?

The registration and verification of sites and activities are to be determined, the applicable data such as facilities, contacts, U.S. agents and importers are to be collated, the facility registration SPL is to be prepared and submitted to the FDA current electronic tool, and the results of acceptance are checked and the documents are to be saved.

(a) The applicable facility in the United States is first registered at a different point than an offshore facility; FDA states that the facilities in its territory are registered within five days of the entry of the drugs into commercial distribution and that the offshore facilities are completed prior to the proposed import of the drugs. The same timetable cannot be applied and it is not appropriate to approach the shipment before addressing information gaps.

How can annual renewals and changes be treated separately?

Reconciling and renewing the registration of facilities from 1 October to 31 December of each year. In the absence of change, the applicable no-change notification process should also be followed; In the event of a change, the current record is updated to make no direct declaration of change for the sake of a renewal.

In the event of a change in information such as location, contact person, business activity, U.S. agent or importer, the corresponding update requirement should be checked. When activities are terminated, operations are withdrawn or write-offs are required, the applicable records should also be maintained, and old information cannot be allowed to lapse.

VI. How to connect to the product listing?

The renewal of the facility and the annual review of listings should be established as two inspection matters. Changes in listings should be updated as soon as possible and no later than June or December, when applicable thereafter; The year shall also identify an update or no change in the certification according to specific records.

Maintained by checking versions and references against current products, labels, production facilities and the previous version of SPL accepted. (b) Keep the submission, the results of the acceptance and the outstanding matters and check whether the public records are consistent with the true business.

VII. Periodicity, costs and common problems

How long will the registration be done?Data collation, DUNS checks, authorizations, system verifications and public queries show that they are distinct and should be scheduled on a realistic basis and that submission or database records cannot be referred to as FDA product approval.

Does every factory have to apply for a Labeler Code?This cannot be inferred. Facilities and codes correspond to different concepts and need to be judged in conjunction with marketing subjects and existing codes.

How do you distinguish the costs?Reconciling general registration submissions, consultants and U.S. agent services, third-party work and user fees such as GDUFA and OMUFA, where applicable; “Submitting itself” and the enterprise's total FDA costs cannot be commingled.

Official sources and service portals

Review of registration and annual maintenance services and preparations for pharmaceutical facilities

Submission of business and product summaries, terms of reference and quotations

Official data checks and updates: 2026-11-06. Author: Mr. Otsun; Audit: Mr. Toto. Specific requirements are based on products, business activities and current FDA applicable rules.

Focus of this paper on relevant topics

This paper focuses on the registration and follow-up maintenance of facilities, in particular the division of labour between annual renewals and updates to listings. The overall sequence of preparation for the first project can be found in the drug registration process, and product codes and details of listings can be found in the NDC Basic Guide.

Continue reading and preparation

Further consolidation of project information is availableRegistration and annual maintenance of pharmaceutical facilities; The scope, processing cycles and costs are shown on the corresponding service page.